Breast · BC

MA.17 showed that extended letrozole after 5 years of tamoxifen reduces recurrence in postmenopausal HR+ early breast cancer. Cited in NCCN BINV-N secondary analyses, with BCI (H/I) high identifying the subgroup most likely to benefit from extended endocrine therapy.

Population: Postmenopausal women with HR+ early breast cancer who had completed about 5 years of adjuvant tamoxifen, randomized to extended endocrine therapy or placebo.

ATAC was the first large trial to show an aromatase inhibitor (anastrozole) superior to tamoxifen for adjuvant endocrine therapy in postmenopausal HR+ early breast cancer, reducing recurrence and contralateral disease with a different toxicity profile (more bone events, fewer thromboembolic and endometrial events).

Population: Postmenopausal women with localized invasive breast cancer (HR-positive majority) completing surgery, randomized to 5 years of anastrozole, tamoxifen, or the combination.

BOLERO-2 was the first phase 3 trial to show that adding a targeted agent (the mTOR inhibitor everolimus) to endocrine therapy improves outcomes in AI-resistant HR+ metastatic disease. Anchored everolimus plus exemestane in NCCN BINV-P as an option after AI progression, especially when CDK4/6 + SERD/fulvestrant options are exhausted.

Population: Postmenopausal women with HR+/HER2- advanced breast cancer who had progressed on a nonsteroidal aromatase inhibitor.

ATLAS (with aTTom) established that extending adjuvant tamoxifen from 5 to 10 years further reduces late recurrence and breast cancer mortality in ER+ disease. Supports NCCN BINV-K extended endocrine therapy options for appropriate patients, particularly those not eligible for AI extension.

Population: Women with ER+ early breast cancer who had completed 5 years of adjuvant tamoxifen, randomized to continue or stop at year 5.

SOFT established that adding OFS to tamoxifen, or using exemestane plus OFS, improves outcomes over tamoxifen alone in premenopausal HR+ early breast cancer, especially in women at sufficient risk to warrant adjuvant chemotherapy. With TEXT it underpins NCCN BINV-K recommendations for OFS in higher-risk premenopausal disease.

Population: Premenopausal women with HR+ early breast cancer who remained premenopausal after surgery (and, if given, adjuvant chemotherapy). Stratified by prior chemotherapy use.

TEXT (combined with SOFT) showed exemestane plus OFS reduced invasive recurrences versus tamoxifen plus OFS in premenopausal HR+ early breast cancer. NCCN BINV-K cites SOFT/TEXT as the basis for AI plus OFS in higher-risk premenopausal disease; 15-year updates confirm durable DFS benefit.

Population: Premenopausal women with HR+ early breast cancer who started OFS (triptorelin) upfront, concurrently with adjuvant chemotherapy when indicated. Joint analysis with SOFT.

PALOMA-3 established palbociclib plus fulvestrant as a standard of care after progression on prior endocrine therapy in HR+/HER2- advanced disease. Included premenopausal women with OFS, extending the CDK4/6 evidence base. Final OS numerically favored palbociclib but missed significance, framing the CDK4/6-class OS debate.

Population: Women with HR+/HER2- advanced breast cancer whose disease progressed on prior endocrine therapy, including premenopausal with OFS.

PALOMA-2 confirmed the PFS benefit of palbociclib plus letrozole in 1L postmenopausal HR+/HER2- metastatic breast cancer and anchored palbociclib's full FDA approval. OS did not reach significance, which -- together with later negative palbociclib OS data -- contributed to ribociclib and abemaciclib gaining OS-based preferred positioning in NCCN.

Population: Postmenopausal women with HR+/HER2- advanced breast cancer with no prior systemic therapy for advanced disease.

MONALEESA-2 established ribociclib plus letrozole in 1L postmenopausal HR+/HER2- metastatic disease. The 2022 final OS analysis showed a 12.5-month median OS improvement -- the first clear OS win for a CDK4/6 inhibitor in 1L postmenopausal, shaping current NCCN preference for ribociclib in this setting.

Population: Postmenopausal women with HR+/HER2- advanced breast cancer and no prior systemic therapy for advanced disease.

MONARCH-2 established abemaciclib plus fulvestrant in post-endocrine-progression HR+/HER2- metastatic disease, with significant PFS and OS benefit. Distinct from palbociclib (PALOMA-3 OS-neutral), it helped differentiate the CDK4/6 class on survival endpoints.

Population: Women with HR+/HER2- advanced breast cancer who had progressed on prior endocrine therapy; premenopausal patients received OFS.

MONARCH-3 established abemaciclib plus nonsteroidal AI in 1L postmenopausal HR+/HER2- metastatic disease, with the longest median PFS among 1L CDK4/6 + AI trials. Final OS was a strong numerical trend but did not reach significance, contributing to nuanced cross-drug comparisons with MONALEESA-2.

Population: Postmenopausal women with HR+/HER2- advanced breast cancer and no prior systemic therapy for metastatic disease.

TAILORx definitively established that most postmenopausal women with HR+/HER2-/N0 disease and RS 11-25 can safely skip adjuvant chemotherapy. NCCN BINV-N category 1 for using the 21-gene assay in this population. In women <=50 years, chemotherapy benefits those with RS 16-25, linking genomic and clinical risk.

Population: Women with HR+/HER2-/node-negative early breast cancer and Oncotype DX 21-gene Recurrence Score (RS) 11-25 (mid-range), randomized to chemoendocrine therapy or endocrine therapy alone.

MONALEESA-3 established ribociclib plus fulvestrant as an OS-improving option in postmenopausal HR+/HER2- 1L or early 2L metastatic disease, and also accommodated men. Consistent with MONALEESA-2/-7 OS benefits, it reinforced the CDK4/6-class OS signal for ribociclib specifically.

Population: Postmenopausal women or men with HR+/HER2- advanced breast cancer, either 1L or early 2L (up to 1 prior endocrine therapy).

MONALEESA-7 was the first CDK4/6 inhibitor trial dedicated to pre/perimenopausal HR+/HER2- metastatic breast cancer and the first to show an OS benefit in this population. Established ribociclib plus endocrine therapy plus OFS as a preferred 1L option for younger women.

Population: Premenopausal or perimenopausal women with HR+/HER2- advanced breast cancer, no prior endocrine therapy for advanced disease (limited prior chemo allowed).

SOLAR-1 established alpelisib plus fulvestrant as the first biomarker-selected targeted option (PIK3CA-mutant) in HR+/HER2- metastatic disease post-endocrine progression. Drove FDA approval May 2019 and NCCN BINV-P recommendation for PIK3CA-mutant tumors; hyperglycemia and rash drive tolerability challenges.

Population: Men and postmenopausal women with HR+/HER2- advanced breast cancer who had progressed on prior endocrine therapy; primary cohort had PIK3CA-mutant tumors.

monarchE established 2-year adjuvant abemaciclib plus endocrine therapy as a new standard for high-risk HR+/HER2- early breast cancer (NCCN v2.2026 category 1). FDA approved October 2021 for node-positive disease with Ki-67 >=20%; label expanded April 2023 to remove the Ki-67 requirement. iDFS benefit deepens with longer follow-up; OS remains a non-significant trend at 5 years.

Population: High-risk HR+/HER2- early breast cancer with node-positive disease (>=4 pos nodes, or 1-3 pos nodes plus high-risk features: Ki-67 >=20%, grade 3, or tumor >=5 cm), after definitive locoregional therapy.

RxPONDER showed that postmenopausal women with 1-3 positive nodes and RS <=25 gain no chemotherapy benefit, while premenopausal women in the same group do benefit -- though part of that benefit likely reflects chemotherapy-induced ovarian suppression. Cited in NCCN BINV-N for node-positive gene expression decisions.

Population: Women with HR+/HER2- breast cancer, 1-3 positive axillary nodes, and Oncotype DX RS <=25, stratified by menopausal status.

DAWNA-1 established dalpiciclib (first Chinese-developed CDK4/6 inhibitor) plus fulvestrant as 2L option for HR+/HER2- MBC progressing on prior endocrine therapy. NMPA approved December 2021. PFS benefit magnitude consistent with global PALOMA-3/MONARCH-2.

Population: HR+/HER2- advanced breast cancer with disease progression on prior endocrine therapy; pre- and postmenopausal women enrolled across China.

EMERALD established elacestrant as the first oral SERD approved in the post-CDK4/6 setting, specifically for ESR1-mutant HR+/HER2- metastatic disease. FDA approved January 2023; NCCN BINV-P lists elacestrant for ESR1-mutant tumors after progression on prior endocrine plus CDK4/6.

Population: Men and postmenopausal women with HR+/HER2- advanced breast cancer who had received 1-2 prior lines including a CDK4/6 inhibitor; included and ESR1-mutant biomarker cohort.

CAPItello-291 established capivasertib plus fulvestrant as a new standard of care for HR+/HER2- advanced disease with AKT-pathway alterations (PIK3CA, AKT1, or PTEN). FDA approved November 2023 for the AKT-altered subset; NCCN BINV-P recommends biomarker-directed use.

Population: Men and women with HR+/HER2- advanced breast cancer who had progressed on or after AI-based therapy, with prior CDK4/6 exposure permitted; defined molecular (AKT-pathway-altered: PIK3CA/AKT1/PTEN) subgroup.

PADA-1 was the first trial to show that ctDNA-guided pre-emptive switching of the AI to fulvestrant (with continued palbociclib) on ESR1 emergence nearly doubles PFS, providing proof-of-concept later confirmed by SERENA-6 with an oral SERD.

Population: Postmenopausal women with HR+/HER2- advanced breast cancer on 1L AI plus palbociclib, without radiographic progression, whose ctDNA monitoring detected an emerging ESR1 mutation.

DAWNA-2 established the China-developed CDK4/6 inhibitor dalpiciclib plus AI as a 1L option for HR+/HER2- metastatic breast cancer in Chinese patients, with a PFS magnitude comparable to global CDK4/6 pivotal trials. NMPA approved dalpiciclib in 2021 (2L) and 2023 (1L) based on DAWNA-1 and DAWNA-2.

Population: Chinese women with HR+/HER2- advanced breast cancer and no prior systemic therapy for advanced disease (1L); endocrine-sensitive.

NATALEE extended the adjuvant CDK4/6 inhibitor benefit to a broader population including selected stage II N0 patients, using a lower 400 mg ribociclib dose for 3 years. FDA approved September 2024 for stage II/III HR+/HER2- at high risk of recurrence. NCCN v2.2026 BINV-16 lists ribociclib as an option for eligible patients; see BINV-K 2 for eligibility.

Population: Stage II-III HR+/HER2- early breast cancer at risk of recurrence, including broader node-negative high-risk (stage IIA N0 with grade 3, or grade 2 plus Ki-67 >=20% or high-risk genomic score) and all stage IIB/III.

postMONARCH showed that switching to abemaciclib plus fulvestrant after CDK4/6 progression provides a modest but significant PFS benefit over fulvestrant alone. Provides prospective phase 3 evidence supporting CDK4/6 switch strategies and is referenced in BINV-P discussions of post-CDK4/6 sequencing.

Population: Women with HR+/HER2- advanced breast cancer who had progressed on a prior CDK4/6 inhibitor plus endocrine therapy; stratified by prior CDK4/6 agent and ESR1/PIK3CA status.

INAVO120 established the first PI3K-alpha selective inhibitor triplet (inavolisib + palbociclib + fulvestrant) in 1L PIK3CA-mutant, endocrine-resistant HR+/HER2- metastatic disease. FDA approved October 2024; NCCN v2.2026 BINV-P lists inavolisib/palbociclib/fulvestrant as a preferred option for PIK3CA-mutant tumors.

Population: Men and women with HR+/HER2- PIK3CA-mutant advanced breast cancer that had progressed on or within 12 months of completing adjuvant endocrine therapy (endocrine-resistant), no prior therapy for advanced disease.

SONIA tested 1L vs 2L CDK4/6 strategy in HR+/HER2- metastatic disease and found no significant PFS2 or OS benefit from routine 1L use over reserving CDK4/6 for 2L. Toxicity and cost were substantially lower in the 2L strategy, challenging the assumption that 1L CDK4/6 is universally preferred.

Population: Postmenopausal women with HR+/HER2- advanced breast cancer, treatment-naive for metastatic disease, randomized to 1L vs 2L use of a CDK4/6 inhibitor.

SERENA-6 was the first phase 3 trial to validate ctDNA-guided pre-emptive switching: detecting emergent ESR1 mutations during 1L AI + CDK4/6 and switching the AI to camizestrant nearly doubled PFS without waiting for radiographic progression. Sets the template for ctDNA-based adaptive endocrine strategy.

Population: Men and postmenopausal women with HR+/HER2- advanced breast cancer on a 1L AI plus CDK4/6 inhibitor, without disease progression, whose ctDNA monitoring detected a new emerging ESR1 mutation.

EMBER-3 showed imlunestrant benefit over SOC in ESR1-mutant disease and significant PFS gain when imlunestrant is combined with abemaciclib, regardless of ESR1 status. NCCN v2.2026 BINV-P adds imlunestrant + abemaciclib as an option in 2L+, most useful in ESR1-mutant disease without prior CDK4/6 exposure.

Population: Men and women with HR+/HER2- advanced breast cancer who had progressed on or after prior AI (with or without CDK4/6 inhibitor); stratified by ESR1 mutation status and prior CDK4/6 exposure.

Birociclib is the next Chinese-developed CDK4/6 inhibitor (after dalpiciclib) in late-stage HR+/HER2- MBC development. Phase 3 readout positions birociclib for NMPA review as another domestic CDK4/6 option. Reinforces Chinese CDK4/6 class maturation beyond dalpiciclib.

Population: HR+/HER2- metastatic breast cancer previously treated with >=1 line of endocrine therapy in the advanced setting; mixed CDK4/6-naive and CDK4/6-experienced populations per cohort.

HERA established 1 year of adjuvant trastuzumab after chemotherapy as standard of care in HER2-positive early breast cancer. Long-term follow-up (2017) confirmed durable benefit and showed 2 years was not superior to 1 year. Anchor trial for NCCN category 1 adjuvant trastuzumab recommendation.

Population: HER2-positive early breast cancer, node-positive or high-risk node-negative, after completion of primary chemotherapy (with or without radiotherapy).

North American sister trials to HERA that established concurrent paclitaxel + trastuzumab in adjuvant therapy. Proved anthracycline --> taxane + trastuzumab (AC-TH) as a standard backbone for HER2+ early breast cancer. NCCN category 1.

Population: HER2-positive operable early breast cancer, node-positive (B-31) or node-positive / high-risk node-negative (N9831), receiving AC followed by paclitaxel-based adjuvant chemotherapy.

EGF104900 was the first trial to prove dual HER2 blockade (lapatinib + trastuzumab) without chemotherapy improves OS in pretreated HER2+ MBC. Supported the mechanistic rationale that later drove CLEOPATRA and APHINITY.

Population: HER2-positive metastatic breast cancer with disease progression on prior trastuzumab-based regimens.

BCIRG-006 validated anthracycline-free TCH as a non-inferior, less cardiotoxic alternative to AC-TH. NCCN includes TCH as preferred regimen for patients with cardiac risk. 10-year follow-up confirmed OS benefit and safety advantage of TCH.

Population: HER2-positive early breast cancer, node-positive or high-risk node-negative, suitable for adjuvant chemotherapy.

NeoSphere first demonstrated that adding pertuzumab to trastuzumab + docetaxel nearly doubles pCR rate in HER2+ breast cancer. Key data supporting FDA accelerated approval of neoadjuvant pertuzumab (2013) -- the first ever neoadjuvant-indication approval.

Population: HER2-positive operable, locally advanced or inflammatory breast cancer >= 2 cm, previously untreated.

CLEOPATRA made pertuzumab + trastuzumab + taxane the 1L standard for HER2+ MBC and set the OS benchmark (~57 months) for the field. NCCN category 1 preferred regimen pre-2026. Still a valid reference arm now challenged by DESTINY-Breast09.

Population: HER2-positive metastatic or locally recurrent breast cancer, no prior chemotherapy or HER2-targeted therapy for metastatic disease.

EMILIA established T-DM1 as 2L standard in HER2+ MBC, ending the reign of lapatinib + capecitabine. FDA approved 2013; held 2L standard until displaced by DESTINY-Breast03 in 2022. Still relevant where T-DXd is not available.

Population: HER2-positive advanced breast cancer previously treated with trastuzumab and a taxane.

TRYPHAENA established cardiac safety and pCR rates for TCHP (the anthracycline-free dual HER2 blockade backbone). Provided the safety rationale that made TCHP the default neoadjuvant regimen for HER2+ disease at most centers.

Population: HER2-positive operable, locally advanced or inflammatory breast cancer >= 2 cm.

TH3RESA extended T-DM1's benefit to heavily pretreated HER2+ MBC, providing a later-line option for patients failing multiple HER2-directed regimens. Supported label expansion beyond 2L.

Population: HER2-positive advanced breast cancer with progression after >= 2 prior HER2-directed regimens including trastuzumab and lapatinib plus a taxane.

APT established weekly paclitaxel + trastuzumab (12 weeks) followed by trastuzumab to 1 year as the standard low-intensity regimen for small, node-negative HER2+ tumors. Avoids anthracycline and pertuzumab exposure with excellent long-term outcomes.

Population: HER2-positive node-negative early breast cancer with tumors up to 3 cm (majority T1, many <=1 cm), considered at low risk of recurrence.

ExteNET established extended adjuvant neratinib for 1 year after completion of trastuzumab in HER2+/HR+ high-risk early breast cancer. FDA-approved 2017; NCCN option for HR+/HER2+ high-risk patients. Diarrhea requires prophylaxis (loperamide).

Population: HER2-positive early breast cancer (mostly node-positive, HR-positive subset drives benefit), within 2 years of completing adjuvant trastuzumab-based therapy.

APHINITY established adjuvant pertuzumab + trastuzumab + chemotherapy as standard for node-positive HER2+ early breast cancer (NCCN category 1). Updated v2.2026 NCCN Footnote mm confirms benefit at 11.3-year follow-up. Benefit limited to node-positive cohort.

Population: HER2-positive early breast cancer, operable, node-positive or high-risk node-negative (pT > 1.0 cm or other high-risk features), after definitive surgery.

MARIANNE failed to show superiority of T-DM1 or T-DM1 + pertuzumab over trastuzumab + taxane in 1L. Cemented CLEOPATRA (pertuzumab + trastuzumab + docetaxel) as unchallenged 1L standard until DESTINY-Breast09.

Population: HER2-positive progressive or recurrent locally advanced or previously untreated metastatic breast cancer.

KRISTINE was a negative chemotherapy-free neoadjuvant experiment: T-DM1 + pertuzumab was inferior to TCHP for pCR and EFS. Established that chemotherapy backbone remains necessary in neoadjuvant HER2+ disease with current ADCs.

Population: HER2-positive stage II-III operable breast cancer >= 2 cm.

KATHERINE established T-DM1 as the standard adjuvant escalation for HER2+ patients who did not achieve pCR after neoadjuvant therapy (NCCN category 1). First trial to demonstrate that residual-disease-driven escalation strategy improves outcomes in HER2+ early breast cancer.

Population: HER2-positive early breast cancer with residual invasive disease in breast or axillary nodes after neoadjuvant chemotherapy plus HER2-targeted therapy (non-pCR).

PHENIX was the pivotal registration trial that earned pyrotinib its first NMPA conditional approval in 2018. Established the platform for later PHOEBE and PHILA. Magnitude of PFS benefit (HR 0.18) is among the largest observed in HER2+ MBC.

Population: HER2-positive metastatic breast cancer previously treated with taxanes, anthracyclines and trastuzumab, Chinese population.

DESTINY-Breast01 launched the T-DXd era with an unprecedented ORR/PFS in heavily pretreated HER2+ MBC. FDA accelerated approval Dec 2019. Also raised the ILD/pneumonitis signal that defines T-DXd safety monitoring.

Population: HER2-positive metastatic breast cancer with progression after T-DM1 (median 6 prior regimens).

HER2CLIMB established tucatinib + trastuzumab + capecitabine as the standard CNS-active regimen for pretreated HER2+ MBC with brain metastases (NCCN preferred). Landmark: first trial to enroll patients with active, untreated brain metastases.

Population: HER2-positive metastatic breast cancer previously treated with trastuzumab, pertuzumab and T-DM1; approximately 48% had brain metastases (including active/progressing).

HOPES established inetetamab (first Chinese-innovated anti-HER2 monoclonal antibody, not biosimilar) + vinorelbine as 1L option for HER2+ MBC. NMPA approved June 2020. Provided domestic alternative to trastuzumab before pyrotinib dominance.

Population: HER2-positive metastatic breast cancer, first-line treatment-naive for advanced disease; stratified by trastuzumab (neo)adjuvant exposure and visceral involvement.

PHOEBE showed pyrotinib + capecitabine outperforms lapatinib + capecitabine in 2L HER2+ MBC. Major regulatory support for NMPA full approval of pyrotinib. Established pyrotinib as standard domestic TKI in China.

Population: HER2-positive metastatic breast cancer previously treated with trastuzumab and taxane (Chinese patients).

DESTINY-Breast03 replaced T-DM1 with T-DXd as 2L HER2+ MBC standard (NCCN category 1). Largest magnitude PFS benefit in the subtype's history (HR 0.33); matched by OS benefit. Defines current 2L standard.

Population: HER2-positive metastatic or unresectable breast cancer previously treated with trastuzumab and taxane.

TUXEDO-1 was the first dedicated trial showing T-DXd achieves a ~73% intracranial response rate in HER2+ brain metastases. Supports T-DXd as an option for symptomatic CNS disease. Small N limits definitive conclusions but signal is strong.

Population: HER2-positive metastatic breast cancer with new or progressive brain metastases after prior HER2-directed therapy; intracranial-only primary endpoint trial.

ATEMPT showed adjuvant T-DM1 yields excellent 3-year iDFS in stage I HER2+ breast cancer and offers a chemotherapy-free alternative to TH. Not designed for formal non-inferiority but supports T-DM1 as an option in selected low-risk patients.

Population: HER2-positive stage I (pT1 N0) early breast cancer considered low risk for recurrence, eligible for adjuvant-only therapy.

DESTINY-Breast02 provided the randomized confirmation (missing from DB-01) that T-DXd beats physician's choice after T-DM1. Reinforces T-DXd as preferred therapy across HER2+ treatment sequence.

Population: HER2-positive metastatic breast cancer with progression after prior T-DM1.

PHILA established pyrotinib + trastuzumab + docetaxel as a Chinese-developed 1L option for HER2+ MBC. NMPA approved 2023; CSCO guideline incorporated. Adds a TKI-based alternative to the pertuzumab-based standard in China.

Population: HER2-positive untreated metastatic or recurrent breast cancer, Chinese patients, first-line setting.

DEBBRAH extended TUXEDO-1 data by documenting T-DXd activity specifically in leptomeningeal disease and stable/progressing brain metastases across multiple HER2 expression levels. Builds evidence base for ADC use in CNS disease.

Population: HER2-positive or HER2-low metastatic breast cancer with leptomeningeal disease or untreated/progressing brain metastases, five cohorts.

SHR-A1811 showed T-DXd-class activity in HER2+ MBC with potentially lower ILD signal. Data supported breakthrough designation and phase 3 HER2-CLIMB-type studies. NMPA accepted NDA; acts as Chinese analogue to T-DXd in the post-trastuzumab 2L/3L HER2+ landscape.

Population: HER2-positive metastatic breast cancer previously treated with trastuzumab and taxane; included post-T-DM1 patients and brain metastasis subset.

DESTINY-Breast09 displaced the 13-year CLEOPATRA standard with T-DXd + pertuzumab as new 1L option for HER2+ MBC. NCCN v2.2026 category 1 (new this cycle). OS data maturing; ILD remains principal safety concern.

Population: HER2-positive metastatic or unresectable breast cancer, first-line therapy, hormone receptor positive or negative.

First pivotal Chinese ADC data showing disitamab vedotin activity in HER2-low MBC prior to DESTINY-Breast04. Supported NMPA approval in gastric cancer and catalyzed further breast RC48 development (RC48-C014 phase 3).

Population: HER2-low (IHC 1+ or 2+/ISH-) metastatic breast cancer previously treated with chemotherapy and endocrine therapy (if HR+); Chinese multicenter phase 1b/2 dose-expansion.

DESTINY-Breast04 created a new actionable breast cancer subtype: HER2-low. FDA approved T-DXd for HER2-low MBC Aug 2022. NCCN category 1; first biologically targeted therapy for what was previously considered HER2-negative disease.

Population: HER2-low (IHC 1+ or 2+/ISH-) metastatic breast cancer, predominantly HR-positive (~88%), previously treated with 1-2 lines of chemotherapy for metastatic disease.

MRG002 (Shanghai Miracogen trastuzumab-MMAE ADC) showed clinically meaningful activity in HER2-low MBC. Distinct from T-DXd payload (DXd topoisomerase I inhibitor) -- MMAE tubulin payload makes it a mechanistically different Chinese HER2 ADC entry.

Population: HER2-low (IHC 1+ or 2+/ISH-) metastatic breast cancer previously treated with chemotherapy; HR+ subgroup required progression on endocrine therapy.

Extended SHR-A1811 activity into HER2-low MBC with ORR approaching DESTINY-Breast04 T-DXd performance. Supports ongoing phase 3 vs chemotherapy in HER2-low setting and positions SHR-A1811 as Chinese competitor across both HER2+ and HER2-low indications.

Population: HER2-low (IHC 1+ or 2+/ISH-) metastatic breast cancer previously treated with >=1 line of chemotherapy; HR+ subgroup required prior endocrine therapy.

DESTINY-Breast06 further extended T-DXd's reach to HER2-ultralow (IHC 0 with staining) MBC after endocrine therapy. FDA approved Jan 2025 for HR+/HER2-low and ultralow post-endocrine. Reshapes chemo-naive MBC sequencing.

Population: HR-positive, HER2-low or HER2-ultralow (IHC 0 with membrane staining) metastatic breast cancer that progressed on >=2 lines of endocrine-based therapy, chemotherapy-naive in the metastatic setting.

BEATRICE showed no iDFS or OS benefit from adding 1 year of adjuvant bevacizumab to standard chemotherapy in early TNBC. Definitively negative result in early breast.

Population: Operable triple-negative invasive breast cancer after surgery and standard (neo)adjuvant chemotherapy; stage I-III.

GeparSixto TNBC cohort showed carboplatin added to anthracycline/taxane/bevacizumab improved pCR and 3-year DFS. Independent corroboration of CALGB-40603 platinum signal.

Population: HER2-negative (TNBC or HER2+ cohort) stage II-III breast cancer in the German GBG network; analysis here focuses on the TNBC subgroup.

CALGB-40603 first demonstrated carboplatin adds meaningful pCR benefit in TNBC neoadjuvant but without clear EFS/OS improvement at 5 years. Bevacizumab gave marginal pCR bump and no survival benefit.

Population: Stage II-III triple-negative breast cancer, treatment-naive, accrued in the US CALGB/Alliance network.

LOTUS showed PFS signal for AKT inhibitor ipatasertib + paclitaxel in 1L metastatic TNBC, enriched in PIK3CA/AKT1/PTEN-altered tumors. Phase 3 IPATunity130 later failed to confirm.

Population: Locally advanced or metastatic triple-negative breast cancer without prior systemic therapy for advanced disease; biomarker-enriched analysis in PTEN-low and PIK3CA/AKT1/PTEN-altered subgroups.

OlympiAD first demonstrated PARP inhibitor superiority over chemotherapy in germline BRCA-mutated HER2-negative metastatic breast (NCCN category 1 preferred; FDA approved January 2018). TNBC subgroup comprised ~50%.

Population: HER2-negative metastatic breast cancer with germline BRCA1/2 pathogenic variant, up to 2 prior chemotherapy lines for metastatic disease (hormone therapy in HR+ allowed).

BrighTNess showed carboplatin added to paclitaxel-AC neoadjuvant improved pCR and long-term EFS in TNBC; adding veliparib to carbo/pac gave no additional benefit. Supports platinum in TNBC neoadjuvant (pre-IO era).

Population: Stage II-III operable triple-negative breast cancer, with or without germline BRCA mutation.

IMpassion130 was first positive IO trial in metastatic TNBC (atezo + nab-paclitaxel, PD-L1+ population) leading to initial FDA accelerated approval. Approval later withdrawn (Aug 2021) after IMpassion131 failed to confirm.

Population: Previously untreated locally advanced or metastatic triple-negative breast cancer, no prior chemotherapy for metastatic disease.

EMBRACA established talazoparib as second PARP inhibitor option in germline BRCA-mutated HER2-negative advanced breast cancer (FDA approved October 2018). PFS benefit similar magnitude to OlympiAD; OS not significant.

Population: HER2-negative locally advanced or metastatic breast cancer with germline BRCA1/2 pathogenic variant; up to 3 prior cytotoxic regimens permitted.

GeparNuevo missed its primary pCR endpoint but showed striking long-term iDFS/OS gains with durvalumab, suggesting IO survival benefit may decouple from pCR. Supportive but not practice-changing.

Population: Early-stage (cT1b-cT4a-d) triple-negative breast cancer, treatment-naive, in the German GBG phase 2 platform.

KEYNOTE-522 established perioperative pembrolizumab + platinum/anthracycline-based chemotherapy as the new standard for stage II-III TNBC (NCCN v2.2026 category 1, preferred). Benefit independent of PD-L1 status. FDA approved July 2021.

Population: Previously untreated non-metastatic (cT1c N1-2 or cT2-4 N0-2) triple-negative breast cancer, regardless of PD-L1 status.

IMpassion031 showed pCR benefit with atezolizumab + nab-paclitaxel/AC neoadjuvant in early TNBC. Conceptually confirmed the KEYNOTE-522 signal but with atezolizumab; FDA accelerated approval for TNBC was later withdrawn after IMpassion131 failed.

Population: Previously untreated stage II-III (cT2-cT4, any N, M0) triple-negative breast cancer, regardless of PD-L1 status.

KEYNOTE-355 established pembrolizumab + chemotherapy as standard 1L in PD-L1 CPS>=10 metastatic TNBC (NCCN category 1; FDA approved November 2020). Benefit restricted to PD-L1-high tumors, confirmed OS gain.

Population: Previously untreated locally recurrent inoperable or metastatic triple-negative breast cancer, at least 6 months since prior (neo)adjuvant chemotherapy.

KEYNOTE-158 supported the tumor-agnostic FDA approval (June 2020) of pembrolizumab for TMB-H unresectable/metastatic solid tumors after prior therapy. Provides a tissue-agnostic option for TMB-H metastatic TNBC beyond PD-L1-directed strategies.

Population: Multi-cohort phase 2 basket trial of advanced solid tumors (including breast) with tumor mutational burden-high (TMB-H, >=10 mut/Mb by FoundationOne CDx), progressed on prior therapy. Subset relevant to TNBC.

PAKT demonstrated capivasertib + paclitaxel extended PFS and suggested OS benefit in 1L metastatic TNBC, particularly in PIK3CA/AKT1/PTEN-altered tumors. Supported pivot of capivasertib development toward HR+ (CAPItello-291).

Population: Metastatic or locally advanced triple-negative breast cancer, no prior chemotherapy for advanced disease; biomarker subgroup defined by PIK3CA/AKT1/PTEN alterations.

IMpassion131 failed to confirm IMpassion130: paclitaxel (instead of nab-paclitaxel) + atezolizumab showed no PFS or OS benefit in PD-L1+ metastatic TNBC. Led to FDA withdrawing atezolizumab TNBC indication in 2021.

Population: Previously untreated locally advanced or metastatic triple-negative breast cancer.

ASCENT established sacituzumab govitecan as standard of care in pretreated metastatic TNBC (NCCN category 1 preferred >=2L; FDA approved April 2021). First TROP2 ADC with OS benefit in any tumor.

Population: Metastatic triple-negative breast cancer (excluding brain metastases in primary analysis) previously treated with >=2 prior lines of chemotherapy including a taxane.

KEYNOTE-119 showed pembrolizumab monotherapy did NOT improve OS over chemotherapy in pretreated metastatic TNBC, even in PD-L1 CPS>=10 subgroup. Negative trial.

Population: Metastatic triple-negative breast cancer previously treated with 1-2 prior systemic regimens for metastatic disease.

OlympiA established adjuvant olaparib x 1 year for germline BRCA1/2 high-risk HER2-negative early breast cancer (NCCN category 1; FDA approved March 2022). First adjuvant PARP inhibitor to improve both iDFS and OS.

Population: HER2-negative early breast cancer with germline BRCA1/2 pathogenic variant and high risk features (TNBC with node-positive or >=cT2/pT2; HR+/HER2- with >=4 positive nodes or failure to achieve pCR with neoadjuvant therapy + high CPS+EG score). TNBC cohort dominant (~82%).

NeoTRIP failed to show pCR or EFS benefit from adding atezolizumab to carboplatin/nab-paclitaxel neoadjuvant without an anthracycline. Suggests anthracycline may be important for IO synergy in TNBC.

Population: Early high-risk (cT1cN1 or cT2-4aN0-3) or locally advanced triple-negative breast cancer.

FUTURE-SUPER established Fudan proprietary TNBC molecular subtyping (FUSCC/Shao) as prospectively actionable, with subtype-matched therapy more than doubling PFS vs nab-paclitaxel alone in 1L mTNBC. Proof-of-concept for precision TNBC.

Population: Previously untreated metastatic triple-negative breast cancer, stratified by FUDAN-TNBC molecular subtype (luminal AR, immunomodulatory, basal-like IR, mesenchymal).

TORCHLIGHT showed toripalimab + nab-paclitaxel significantly prolonged PFS in PD-L1 CPS>=1 mTNBC vs chemo alone. NMPA approved toripalimab for 1L PD-L1+ mTNBC in 2023. First positive Chinese IO+chemo phase 3 in TNBC, mirroring KEYNOTE-355.

Population: Previously untreated or taxane-naive metastatic or recurrent triple-negative breast cancer; stratified by PD-L1 CPS status (>=1 vs <1).

Camrelizumab + nab-paclitaxel in 1L PD-L1+ mTNBC. Supports second Chinese PD-1 (after TORCHLIGHT) positive phase 3 in TNBC IO+chemo space. Likely NMPA submission for PD-L1+ mTNBC indication expansion.

Population: Previously untreated locally advanced or metastatic triple-negative breast cancer; PD-L1 CPS>=1 required for primary analysis population.

ASCENT-04 showed sacituzumab govitecan + pembrolizumab improves PFS over pembrolizumab + chemotherapy in PD-L1 CPS>=10 1L metastatic TNBC. Basis for NCCN v2.2026 upgrade of saci + pembro to category 1 first-line.

Population: Previously untreated locally advanced unresectable or metastatic triple-negative breast cancer with PD-L1 CPS>=10.

TROPION-Breast02 demonstrated datopotamab deruxtecan superior to chemotherapy in IO-ineligible 1L metastatic TNBC. Basis for NCCN v2.2026 listing of datopotamab as a preferred recommendation in first line.

Population: Previously untreated locally recurrent inoperable or metastatic triple-negative breast cancer, not candidates for PD-(L)1 inhibitors (PD-L1 low/negative, or contraindication).